Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.

Journal Article (Clinical Trial;Clinical Trial, Phase III;Journal Article;Multicenter Study)

BACKGROUND: Thymoglobulin, a rabbit anti-human thymocyte globulin, was compared with Atgam, a horse anti-human thymocyte globulin for the treatment of acute rejection after renal transplantation. METHODS: A multicenter, double-blind, randomized trial with enrollment stratification based on standardized histology (Banff grading) was conducted. Subjects received 7-14 days of Thymoglobulin (1.5 mg/kg/ day) or Atgam (15 mg/kg/day). The primary end point was rejection reversal (return of serum creatinine level to or below the day 0 baseline value). RESULTS: A total of 163 patients were enrolled at 25 transplant centers in the United States. No differences in demographics or transplant characteristics were noted. Intent-to-treat analysis demonstrated that Thymoglobulin had a higher rejection reversal rate than Atgam (88% versus 76%, P=0.027, primary end point). Day 30 graft survival rates (Thymoglobulin 94% and Atgam 90%, P=0.17), day 30 serum creatinine levels as a percentage of baseline (Thymoglobulin 72% and Atgam 80%; P=0.43), and improvement in posttreatment biopsy results (Thymoglobulin 65% and Atgam 50%; P=0.15) were not statistically different. T-cell depletion was maintained more effectively with Thymoglobulin than Atgam both at the end of therapy (P=0.001) and at day 30 (P=0.016). Recurrent rejection, at 90 days after therapy, occurred less frequently with Thymoglobulin (17%) versus Atgam (36%) (P=0.011). A similar incidence of adverse events, post-therapy infections, and 1-year patient and graft survival rates were observed with both treatments. CONCLUSIONS: Thymoglobulin was found to be superior to Atgam in reversing acute rejection and preventing recurrent rejection after therapy in renal transplant recipients.

Full Text

Duke Authors

Cited Authors

  • Gaber, AO; First, MR; Tesi, RJ; Gaston, RS; Mendez, R; Mulloy, LL; Light, JA; Gaber, LW; Squiers, E; Taylor, RJ; Neylan, JF; Steiner, RW; Knechtle, S; Norman, DJ; Shihab, F; Basadonna, G; Brennan, DC; Hodge, EE; Kahan, BD; Kahan, L; Steinberg, S; Woodle, ES; Chan, L; Ham, JM; Schroeder, TJ

Published Date

  • July 15, 1998

Published In

Volume / Issue

  • 66 / 1

Start / End Page

  • 29 - 37

PubMed ID

  • 9679818

Pubmed Central ID

  • 9679818

International Standard Serial Number (ISSN)

  • 0041-1337

Digital Object Identifier (DOI)

  • 10.1097/00007890-199807150-00005


  • eng

Conference Location

  • United States